| Summary Of Investments Held By The Plan |
The Plan’s investment in Company common stock experienced net appreciation / (depreciation) in value as follows for the years ended June 30, 2026, 2025, and 2024: | | | | | | | | | | | | | 2026 £ | 2025 £ | 2024 £ | | The Procter & Gamble Company | | | | | common stock: | | | | | Net (depreciation) / appreciation | (4,717,597) | (11,093,993) | 1,489,489 |
The realized gain on shares sold of Company common stock for the years ended June 30, 2026, 2025 and 2024, was determined using an average cost method as follows: | | | | | | | | | | | | | | | | | | | 2026 £ | | 2025 £ | | 2024 £ | | Proceeds on sale of shares | 8,146,619 |
| 9,199,905 | | 10,534,286 | | Cost | (6,395,108) | | (5,882,550) | | (6,573,003) | | Realized gain on shares sold | 1,751,511 | | 3,317,355 | | 3,961,283 |
|